Publication
FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer.
Authors not recorded
Clin Cancer Res2019PMID 31371343PMC6825550stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerMalignant Breast Neoplasmcivic_curation1.00
- drugEndocrine Drug Therapycivic_curation1.00
- drugEverolimuscivic_curation1.00
- geneFGFR1civic_curation1.00
- variantFGFR1 Amplificationcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 31371343
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| FGFR1 Amplification1 | ||||||||
| Endocrine Drug Therapy + EverolimusCombination | Malignant Breast Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID12498In a clinical cohort of patients with HR+/HER2- metastatic breast cancer (n=110), FGFR1 amplification status was determined using FISH analysis (FGFR1/centromere 8 ratio ≥2). Among those receiving end… (full text at CIViC) PMID 31371343 · Drago et al., 2019 · Open in CIViC | civic |